CN113462772A - 一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 - Google Patents
一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 Download PDFInfo
- Publication number
- CN113462772A CN113462772A CN202111029448.2A CN202111029448A CN113462772A CN 113462772 A CN113462772 A CN 113462772A CN 202111029448 A CN202111029448 A CN 202111029448A CN 113462772 A CN113462772 A CN 113462772A
- Authority
- CN
- China
- Prior art keywords
- allele type
- artificial sequence
- dna
- nicotine
- allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 18
- 229960002715 nicotine Drugs 0.000 title claims abstract description 18
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 230000001419 dependent effect Effects 0.000 title claims abstract description 14
- 239000002773 nucleotide Substances 0.000 title claims description 8
- 125000003729 nucleotide group Chemical group 0.000 title claims description 8
- 206010057852 Nicotine dependence Diseases 0.000 claims abstract description 28
- 208000025569 Tobacco Use disease Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 9
- 108700028369 Alleles Proteins 0.000 claims description 90
- 102220006047 rs1051730 Human genes 0.000 claims description 8
- 102200143520 rs6265 Human genes 0.000 claims description 8
- 102210008249 rs1451240 Human genes 0.000 claims description 7
- 102220406030 rs3733829 Human genes 0.000 claims description 7
- 102220406029 rs6474412 Human genes 0.000 claims description 7
- 102210039820 rs2036527 Human genes 0.000 claims description 6
- 102200051916 rs16969968 Human genes 0.000 claims description 5
- 102210040020 rs6495308 Human genes 0.000 claims description 5
- 102210036430 rs7937 Human genes 0.000 claims description 5
- 108010006785 Taq Polymerase Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 64
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000000391 smoking effect Effects 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000745175 Homo sapiens Neuronal acetylcholine receptor subunit alpha-5 Proteins 0.000 description 3
- 101000678747 Homo sapiens Neuronal acetylcholine receptor subunit beta-4 Proteins 0.000 description 3
- 102100022728 Neuronal acetylcholine receptor subunit beta-4 Human genes 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101150103822 Chrnb2 gene Proteins 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 101000745163 Homo sapiens Neuronal acetylcholine receptor subunit alpha-3 Proteins 0.000 description 2
- 101000726905 Homo sapiens Neuronal acetylcholine receptor subunit beta-3 Proteins 0.000 description 2
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 description 2
- 101000723815 Homo sapiens Zinc finger CCHC domain-containing protein 14 Proteins 0.000 description 2
- 102100039908 Neuronal acetylcholine receptor subunit alpha-3 Human genes 0.000 description 2
- 102100039907 Neuronal acetylcholine receptor subunit alpha-5 Human genes 0.000 description 2
- 102100030911 Neuronal acetylcholine receptor subunit beta-3 Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102100020982 Regulator of G-protein signaling 17 Human genes 0.000 description 2
- 101710148109 Regulator of G-protein signaling 17 Proteins 0.000 description 2
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 2
- 102100028477 Zinc finger CCHC domain-containing protein 14 Human genes 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 201000006152 substance dependence Diseases 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101150007447 CHRNA3 gene Proteins 0.000 description 1
- 101150035854 CYP2A6 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100031192 Chondroitin sulfate N-acetylgalactosaminyltransferase 1 Human genes 0.000 description 1
- 101150090987 Chrnb4 gene Proteins 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000017695 GABRA2 Human genes 0.000 description 1
- 101000776615 Homo sapiens Chondroitin sulfate N-acetylgalactosaminyltransferase 1 Proteins 0.000 description 1
- 101000893333 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-2 Proteins 0.000 description 1
- 101000577424 Homo sapiens Proteasome subunit alpha type-4 Proteins 0.000 description 1
- 101000743853 Homo sapiens Ras-related protein Rab-4B Proteins 0.000 description 1
- 101000963987 Homo sapiens SH3 domain-binding protein 5 Proteins 0.000 description 1
- 101000740755 Homo sapiens Voltage-dependent calcium channel subunit alpha-2/delta-1 Proteins 0.000 description 1
- 102100021101 Hydroxylysine kinase Human genes 0.000 description 1
- 108010003207 Hydroxylysine kinase Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030912 Neuronal acetylcholine receptor subunit beta-2 Human genes 0.000 description 1
- 102100028448 Nuclear receptor subfamily 2 group C member 2 Human genes 0.000 description 1
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 description 1
- 102100028813 Proteasome subunit alpha type-4 Human genes 0.000 description 1
- 102100039101 Ras-related protein Rab-4B Human genes 0.000 description 1
- 102100040119 SH3 domain-binding protein 5 Human genes 0.000 description 1
- 108091006685 SLCO3A1 Proteins 0.000 description 1
- 102100022000 Solute carrier organic anion transporter family member 3A1 Human genes 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102100037059 Voltage-dependent calcium channel subunit alpha-2/delta-1 Human genes 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于检测尼古丁依赖性相关的SNP位点的引物组以及应用，引物组包括26对引物对，引物对的核苷酸序列如SEQ ID NO.1‑52所示；应用于检测尼古丁依赖易感性产品中以及试剂盒中；本发明能够有效提高检测的效率；特异性强，灵敏度高，针对不同个体的适用性较好，整个鉴定流程容易理解，操作简便，结果准确可靠，应用广泛，该方法操作简便，结果准确可靠。
Description
技术领域
本发明涉及生物技术领域，特别涉及一种用于检测尼古丁依赖性相关的SNP位点的引物组以及应用。
香烟是最广泛滥用物质之一，香烟内导致成瘾的主要物质为尼古丁，尼古丁依赖（Nicotine Dependence，NP）符合 DSM-Ⅳ中对物质依赖的诊断标准，包括冲动性使用，停药困难以及慢性使用后停药产生戒断症状，其中心理依赖是物质依赖最核心的特征之一。目前，尼古丁依赖已成为全球关注的一个严重问题。据世界卫生组织估计，目前全球每年约有500万人死于由吸烟所引发的包括癌症、心血管疾病以及肺部疾病，预计2030 年每年因吸烟致死的人数将达到1000万。
吸烟与尼古丁依赖的分子遗传学机制：随着候选基因及 GWAS（Genome WideAssociated Study）研究，目前吸烟与尼古丁依赖的分子遗传学研究取得了一定进展。研究发 CHRNB2 基因的单核苷酸多态（single nucleotide polymorphism, SNP）与戒烟能力之间存在强相关性，而位于 CHRNB2 与 CHRNB4 基因的 SNPs 之间的交互作用提示二者影响尼古丁依赖。2007 年研究发现位于 CHRNA5 基因的 rs16969968 是尼古丁依赖的易感因素,另外几个独立研究随后验证该位点和位于 CHRNA3 rs1051730 与尼古丁依赖剂量包括每日吸烟数量（cigarettes per day, CPD）以及尼古丁依赖程度呈高度相关性。GWAS 研究显示位于第 15 号染色体上的 CHRNB5-CHRNA3-CHRNB4 基因束与 CPD 具有相关性，第 8号染色体上的 CHRNB3-CHRNA6 以及第 2 号染色体上的骨骼肌 CHRND-CHRNG基因束均与尼古丁依赖以及吸烟有强相关性。最近来自TGC（the Tobacoo and Genetics Consortium）针对欧美国家人群（n=140，023）的全基因组关联分析及 Meta 分析鉴定了一系列与吸烟行为相关的位点；其中3个位点与每日吸烟量关联，包括位于10q25的rs1329650和rs1028936，以及位于 9q13 的 EGLN2 基因内的rs3733829和位于15q25的CHRNA3 基因的 rs1051730。rs3733829 在 CYP2A6 （Cytochrome P450 2A6）基因 3’端下游 40Kb 处，等位基因 G 的每个拷贝增加约 0.5CPD，CYP2A6 基因是吸烟的一个候选基因，是一种代谢酶可将尼古丁代谢为可替宁，CYP2A6 的某些突变可因减慢尼古丁代谢而减少尼古丁摄人。rs1051730 的A 等位基因与每日吸烟量具有最强关联性， P 值为 2.8×10-7；有 8 个 SNPs 与起动吸烟有关，最强关联性位点为第 11 号染色体上BDNF(Brain-derived neurotrophicfactor)基因的 rs6265 的Ｃ等位基因；此外，位于9号染色体上的DBH(Dopamine-hydroxylase)基因附近的 rs3025343 的G 等位基因与吸烟戒断具有关联性。由此可见,遗传学风险因素在尼古丁依赖致病机制中起重要作用。
国内尼古丁依赖的易感基因关联研究尚存在以下问题：1、尚无在同一人群背景中进行尼古丁依赖与多易感基因位点联合研究；2、尚无近年基于大样本量 GWAS 研究鉴定的新易感基因关联研究；3、尚无尼古丁依赖与多易感基因及性格因素关联性的联合研究。
发明内容
我们通过在同一大样本人群背景下同时对若干易感基因位点进行研究，发现与中国汉族人群尼古丁依赖最相关的易感基因SNPs，并设计相应的引物组合，该组合可用于检测中国汉族人群个体的尼古丁依赖易感性，也为开发预防尼古丁依赖的药物提供了依据。
发明的目的在于提供一种用于检测尼古丁依赖性相关的SNP位点的引物组以及应用，解决了背景技术中存在的问题。
本发明是这样实现的，一种用于检测尼古丁依赖性相关的SNP位点的引物组，所述引物组包括26对引物对，所述引物对的核苷酸序列如表1中的SEQ ID NO.1-52所示。
表1
本发明的进一步技术方案是：所述引物组对应的SNP位点为：rs1318937、rs17040623、rs279871、rs2349433、rs7747583、rs13225753、rs1451240、rs6474412、rs6996964、rs1028936、rs1329650、rs6265、rs1051730、rs16969968、rs2036527、rs4887077、rs6495308、rs6495309、rs6495314、rs7163369、rs8034191、rs13334632、rs2241617、rs7937、rs3733829、rs4105144。
本发明的进一步技术方案是：rs1318937等位基因型为A/G、rs17040623等位基因型为A/G、rs279871等位基因型为C/T、rs2349433等位基因型为G/A、rs7747583等位基因型为C/A、rs13225753等位基因型为A/G、rs1451240等位基因型为G/A、rs6474412等位基因型为T/C、rs6996964等位基因型为C/T、rs1028936等位基因型为C/A、rs1329650等位基因型为T/G、rs6265等位基因型为T/C、rs1051730等位基因型为G/A、rs16969968等位基因型为G/A，rs2036527等位基因型为G/A、rs4887077等位基因型为C/T、rs6495308等位基因型为C/T、rs6495309等位基因型为C/T、rs6495314等位基因型为A/C、rs7163369等位基因型为A/G、rs8034191等位基因型为T/C、rs13334632等位基因型为T/C、rs2241617等位基因型为C/T、rs7937等位基因型为T/C、rs3733829等位基因型为A/G、rs4105144等位基因型为C/T。
一种用于检测尼古丁依赖性相关的SNP位点的引物组的应用，应用于检测尼古丁依赖易感性产品中。
本发明的进一步技术方案是：所述产品包括试剂、制剂以及装置。
本发明的进一步技术方案是：用于检测尼古丁依赖易感性试剂盒，所述试剂盒还包括Taq DNA聚合酶、10x buffer以及dNTP。
本发明的进一步技术方案是：待测样品来自待测个体的血液、尿、唾液、胃液、头发或活组织检查。
本发明的有益效果：(1)本发明提供的26个SNP位点基于中国人群全基因组测序数据关联分析得到，与中国人群中的尼古丁依赖易感性具有较强的相关性，能够有效提高检测的效率；
(2)本发明开发的用于扩增上述SNP位点的引物对，特异性强，灵敏度高，针对不同个体的适用性较好，整个鉴定流程容易理解，操作简便，结果准确可靠，可以广泛应用于中国人群个体中上述SNP位点的鉴定；
(3)本发明提供了一种鉴定上述SNP位点等位基因型的试剂盒的应用方法，该方法操作简便，结果准确可靠。
具体实施方式
下面结合具体实施例对本发明作进一步的说明。
实施例一：
一种用于检测尼古丁依赖性相关的SNP位点的引物组，所述引物组包括26对引物对，所述引物对的核苷酸序列如SEQ ID NO.1-52所示。
实施例二：
外周血采集及DNA提取：
外周血采血一般采用真空采血管采集，收集好的全血应在5min中内用液氮速冻，保存于-80℃冰箱。加入EDTA抗凝剂后的新鲜血液一般可以在4℃放置12-24小时。务必保证经过速冻后的样本要低温保存，且必须避免反复冻融。
本发明中的外周血DNA提取包括以下步骤：首先向2mL全血中加入5倍体积的1x红细胞裂解液，涡旋并弃上清；然后加入白细胞裂解液0.5mL和20mg/ml蛋白酶K 20μL，37℃水浴裂解白细胞至沉淀溶解；再加入等体积的氯仿待分层后转移上清至新EP管中，加入1/10体积的3M醋酸铵和等体积的冰乙醇沉淀DNA，用1mL的体积浓度为75％乙醇洗涤后自然干燥，加入TE溶解即可得到DNA。为确保后续血液样本的核酸提取质量合格，每个样本应提取1μg以上的全基因组DNA，浓度>12.5ng/μL，OD260/280在1.8～2.0之间。DNA质量检测包括完整性、总量及浓度的检测，可采用Qubit或AGE仪器完成。DNA样品含量检测可采用以下两种方法的一种：荧光定量或琼脂糖凝胶电泳检测。荧光定量主要对样品浓度进行精确定量(如Qubit Fluorometer)，琼脂糖凝胶电泳使用质量浓度为1％的琼脂糖凝胶在150V电压下电泳约40min(缓冲液为1xTAE)，检测样品完整性及是否存在RNA、蛋白和次生代谢物污染。根据DNA总量和浓度对血样给出等级判定。优：DNA总量≥2μg、浓度≥12.5ng/μL且样品没有降解或者轻微降解。良：DNA总量介于1～2μg、浓度≥12.5ng/μL且样品没有降解或者轻微降解。尽量选用质量检测为优的DNA样品进行后续的工作。
单核苷酸多态性检测：
利用本发明中根据基因多态性区域特征设计的引物对，以上述DNA样品为模板进行PCR扩增得到包含多态性区域的DNA片段。具体如下：
PCR反应20μL体系：Taq DNA聚合酶1μL，正向引物10pmol/μL 0.6μL，反向引物10pmol/μL 0.6μL，模板DNA 2μL，10x buffer 2μL，dNTP 2.5mM 1.8mL，ddH2O 12.0μL，总计20μL。
PCR反应条件如下：94℃预变性3min；94℃变性45s，59℃退火45s，72℃延伸45s，共50个循环；72℃最后延伸5min，4℃保存。
PCR扩增完成后用琼脂糖凝胶电泳检测，切胶回收产物，随后用sanger测序得到样本中上述单核苷酸多态性位点的基因型。
实施例三：
本发明提供了一系列与尼古丁依赖风险相关的单核苷酸多态性位点(SNP)。本发明在1496个中国人群样本中进行基因分型和表型关联分析，得到了26个与中国汉族人群尼古丁依赖相关的SNP。所述SNP位点的物理位置是根据人参考基因组GRCh37/hg19确定的，SNP的编号的来源为dbSNP151。所述的SNP在人基因组的染色体及位置如表2所示。
表2 中国人群尼古丁依赖相关的26个SNPs位点所在染色体及位置
| 单核苷酸多态位点 | 染色体 | 基因 | 位置(hg19) |
| rs1318937 | 3 | SH3BP5 | chr3:15,295,364-15,295,364 |
| rs17040623 | 3 | NR2C2 | chr3:15,028,478-15,028,478 |
| rs279871 | 4 | GABRA2 | chr4:46,305,733-46,305,733 |
| rs2349433 | 6 | RGS17 | chr6:153,383,755-153,383,755 |
| rs7747583 | 6 | RGS17 | chr6:153,371,768-153,371,768 |
| rs13225753 | 7 | CACNA2D1 | chr7:82,158,523-82,158,523 |
| rs1451240 | 8 | CHRNB3 | chr8:42,546,751-42,546,751 |
| rs6474412 | 8 | CHRNB3 | chr8:42,550,498-42,550,498 |
| rs6996964 | 8 | CSGALNACT1 | chr8:19,623,911-19,623,911 |
| rs1028936 | 10 | HECTD2-AS1 | chr10:93,349,797-93,349,797 |
| rs1329650 | 10 | HECTD2-AS1 | chr10:93,348,120-93,348,120 |
| rs6265 | 11 | BDNF | chr11:27,679,916-27,679,916 |
| rs1051730 | 15 | CHRNA3 | chr15:78,894,339-78,894,339 |
| rs16969968 | 15 | CHRNA5 | chr15:78,882,925-78,882,925 |
| rs2036527 | 15 | PSMA4//CHRNA5 | chr15:78,851,615-78,851,615 |
| rs4887077 | 15 | CHRNB4 | chr15:78,978,364-78,978,364 |
| rs6495308 | 15 | CHRNA3 | chr15:78,907,656-78,907,656 |
| rs6495309 | 15 | CHRNB4 | chr15:78,915,245-78,915,245 |
| rs6495314 | 15 | CHRNB4 | chr15:78,960,529-78,960,529 |
| rs7163369 | 15 | SLCO3A1 | chr15:92,533,914-92,533,914 |
| rs8034191 | 15 | HYKK | chr15:78,806,023-78,806,023 |
| rs13334632 | 16 | ZCCHC14 | chr16:87,490,819-87,490,819 |
| rs2241617 | 16 | ZCCHC14 | chr16:87,441,048-87,441,048 |
| rs7937 | 19 | RAB4B | chr19:41,302,706-41,302,706 |
| rs3733829 | 19 | EGLN2 | chr19:41,310,571-41,310,571 |
| rs4105144 | 19 | CYP2A6 | chr19:41,358,624-41,358,624 |
所述引物组对应的SNP位点为：rs1318937、rs17040623、rs279871、rs2349433、rs7747583、rs13225753、rs1451240、rs6474412、rs6996964、rs1028936、rs1329650、rs6265、rs1051730、rs16969968、rs2036527、rs4887077、rs6495308、rs6495309、rs6495314、rs7163369、rs8034191、rs13334632、rs2241617、rs7937、rs3733829、rs4105144。
rs1318937等位基因型为A、rs17040623等位基因型为A、rs279871等位基因型为C、rs2349433等位基因型为G、rs7747583等位基因型为C、rs13225753等位基因型为A、rs1451240等位基因型为G、rs6474412等位基因型为T、rs6996964等位基因型为C、rs1028936等位基因型为C、rs1329650等位基因型为T、rs6265等位基因型为C、rs1051730等位基因型为G、rs16969968等位基因型为G，rs2036527等位基因型为G、rs4887077等位基因型为C、rs6495308等位基因型为C、rs6495309等位基因型为C、rs6495314等位基因型为A、rs7163369等位基因型为A、rs8034191等位基因型为T、rs13334632等位基因型为T、rs2241617等位基因型为C、rs7937等位基因型为T、rs3733829等位基因型为A、rs4105144等位基因型为C。
实施例四：
一种用于检测尼古丁依赖性相关的SNP位点的引物组的应用，应用于检测尼古丁依赖易感性产品中，所述产品包括试剂、制剂、试剂盒以及装置。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
序列表
<110> 中南大学湘雅医院
<120> 一种用于检测尼古丁依赖性相关的SNP位点的引物组以及应用
<160> 52
<170> SIPOSequenceListing 1.0
<210> 1
<211> 24
<212> DNA
<213> 人工序列(artificial sequence)
<400> 1
actccttccc actttcattc tctg 24
<210> 2
<211> 24
<212> DNA
<213> 人工序列(artificial sequence)
<400> 2
actgagactt gcttgactta ccat 24
<210> 3
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 3
ataggagtgc cacccaaacg 20
<210> 4
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 4
aacataatta tcagtctcct tgcct 25
<210> 5
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 5
agaagctcaa ggagtaatag tcaat 25
<210> 6
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 6
gtgagctgca agtttcttga t 21
<210> 7
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 7
tgccactgtg ggctaaagta cc 22
<210> 8
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 8
gtggttagaa gaggggaata acagc 25
<210> 9
<211> 24
<212> DNA
<213> 人工序列(artificial sequence)
<400> 9
atcaattttg gaagagtact tggg 24
<210> 10
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 10
aaaggtttga gtttctccag tgt 23
<210> 11
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 11
accacataac caaagcacag tt 22
<210> 12
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 12
ctcagtatgg cagcgaatag a 21
<210> 13
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 13
acaaagtgtg gacgctcctg 20
<210> 14
<211> 19
<212> DNA
<213> 人工序列(artificial sequence)
<400> 14
cgtgaccagg aagatcccg 19
<210> 15
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 15
tgtagtgagg cgagattgcg 20
<210> 16
<211> 19
<212> DNA
<213> 人工序列(artificial sequence)
<400> 16
gccacctttc tccctgcaa 19
<210> 17
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 17
ggcaacacca ctcaaaccac 20
<210> 18
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 18
cctggaacat ggtgcaagtc 20
<210> 19
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 19
cagtacgcag aggagtcagg 20
<210> 20
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 20
gcgtgaaatc tcttgcagcc 20
<210> 21
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 21
gggatgaaaa cagaactacc cct 23
<210> 22
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 22
ggtgtcgggg gagatgtttc 20
<210> 23
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 23
gctccaaagg cacttgacta c 21
<210> 24
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 24
gcttgacatc attggctgac a 21
<210> 25
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 25
acagcgagta tgtgatgtcg g 21
<210> 26
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 26
agttcggttc ctggtcctac 20
<210> 27
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 27
cgcctttggt ccgcaagata 20
<210> 28
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 28
ctcacggaca tcattttcct tca 23
<210> 29
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 29
gtgagacagc tgtggaactg ga 22
<210> 30
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 30
gaaacaagac cagatgagca acc 23
<210> 31
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 31
tctgcacctg ggctgttaga 20
<210> 32
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 32
tgcctgtccc cttttaggga 20
<210> 33
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 33
tcctttctcc aaggcccaga 20
<210> 34
<211> 19
<212> DNA
<213> 人工序列(artificial sequence)
<400> 34
cgatgctgtg atcaggggg 19
<210> 35
<211> 25
<212> DNA
<213> 人工序列(artificial sequence)
<400> 35
gaaagtctca atggtaagaa aacga 25
<210> 36
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 36
ccattttgca atcccaccaa agt 23
<210> 37
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 37
cctgaagaga ggcagagcag 20
<210> 38
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 38
aagccaggag gatgcagaac 20
<210> 39
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 39
ttgtgtatta ccaaatgccc ctg 23
<210> 40
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 40
aggcaacagc aaatgcgtca 20
<210> 41
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 41
ggtggttgtg ttttcggtgc 20
<210> 42
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 42
ttcccctgat ttccacaagt cc 22
<210> 43
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 43
gtacggggtt tactaggcta caa 23
<210> 44
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 44
gtggctggct gaagaaaata gc 22
<210> 45
<211> 23
<212> DNA
<213> 人工序列(artificial sequence)
<400> 45
ccatttcctc agtgctcttt agc 23
<210> 46
<211> 22
<212> DNA
<213> 人工序列(artificial sequence)
<400> 46
ctccaagaat ggggaaagtg ga 22
<210> 47
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 47
gaagggggaa tcccgtacct 20
<210> 48
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 48
gctttatggg ggtagggtgg 20
<210> 49
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 49
attgtgggaa gagggtgcag 20
<210> 50
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 50
accacctcac tgggagaaga 20
<210> 51
<211> 20
<212> DNA
<213> 人工序列(artificial sequence)
<400> 51
tgtgtggagg gaacaaaggt 20
<210> 52
<211> 21
<212> DNA
<213> 人工序列(artificial sequence)
<400> 52
ccagtgagaa acaaactccc c 21
Claims (6)
1.一种用于检测尼古丁依赖性相关的SNP位点的引物组，其特征在于：所述引物组包括26对引物对，所述引物对的核苷酸序列如SEQ ID NO.1-52所示。
2.根据权利要求1所述的一种用于检测尼古丁依赖性相关的SNP位点的引物组，其特征在于：所述引物组对应的SNP位点为：rs1318937、rs17040623、rs279871、rs2349433、rs7747583、rs13225753、rs1451240、rs6474412、rs6996964、rs1028936、rs1329650、rs6265、rs1051730、rs16969968、rs2036527、rs4887077、rs6495308、rs6495309、rs6495314、rs7163369、rs8034191、rs13334632、rs2241617、rs7937、rs3733829、rs4105144。
3.根据权利要求2所述的一种用于检测尼古丁依赖性相关的SNP位点的引物组，其特征在于：rs1318937等位基因型为A、rs17040623等位基因型为A、rs279871等位基因型为C、rs2349433等位基因型为G、rs7747583等位基因型为C、rs13225753等位基因型为A、rs1451240等位基因型为G、rs6474412等位基因型为T、rs6996964等位基因型为C、rs1028936等位基因型为C、rs1329650等位基因型为T、rs6265等位基因型为C、rs1051730等位基因型为G、rs16969968等位基因型为G，rs2036527等位基因型为G、rs4887077等位基因型为C、rs6495308等位基因型为C、rs6495309等位基因型为C、rs6495314等位基因型为A、rs7163369等位基因型为A、rs8034191等位基因型为T、rs13334632等位基因型为T、rs2241617等位基因型为C、rs7937等位基因型为T、rs3733829等位基因型为A、rs4105144等位基因型为C。
4.根据权利要求1-3中任意一项所述一种用于检测尼古丁依赖性相关的SNP位点的引物组的应用，其特征在于：应用于检测尼古丁依赖易感性产品中。
5.根据权利要求4所述一种用于检测尼古丁依赖性相关的SNP位点的引物组的应用，其特征在于：所述产品包括试剂、制剂以及装置。
6.根据权利要求1-3中任意一项所述一种用于检测尼古丁依赖性相关的SNP位点的引物组的应用，其特征在于：用于检测尼古丁依赖易感性试剂盒，所述试剂盒还包括Taq DNA聚合酶、10x buffer以及dNTP。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111029448.2A CN113462772B (zh) | 2021-09-03 | 2021-09-03 | 一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111029448.2A CN113462772B (zh) | 2021-09-03 | 2021-09-03 | 一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113462772A true CN113462772A (zh) | 2021-10-01 |
| CN113462772B CN113462772B (zh) | 2021-11-16 |
Family
ID=77867220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111029448.2A Active CN113462772B (zh) | 2021-09-03 | 2021-09-03 | 一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113462772B (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012356A2 (en) * | 2004-06-23 | 2006-02-02 | Washington University | Methods for determining risk of developing regular smoking behavior |
| CN101050212A (zh) * | 2007-05-18 | 2007-10-10 | 中南大学 | 从废次烟草中同时提取高纯天然烟碱和茄尼醇的方法 |
| WO2008086579A1 (en) * | 2007-01-19 | 2008-07-24 | Queensland University Of Technology | Diagnostic methods and agents |
| WO2013036938A1 (en) * | 2011-09-08 | 2013-03-14 | The Ohio State University | Materials and methods related to dopamine dysregulation disorders |
| CN108251520A (zh) * | 2018-01-31 | 2018-07-06 | 杭州同欣基因科技有限公司 | 一种基于高通量测序技术的吸烟成瘾风险预测方法及戒烟指导方法 |
| CN110317868A (zh) * | 2019-08-09 | 2019-10-11 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN110910956A (zh) * | 2019-11-21 | 2020-03-24 | 刘强 | 单核苷酸多态性检测汉族人群吸烟成瘾方法 |
| CN111518896A (zh) * | 2020-06-28 | 2020-08-11 | 云南中烟工业有限责任公司 | 用于检测尼古丁依赖相关的snp位点的引物组、应用、产品及方法 |
| CN111826436A (zh) * | 2020-07-21 | 2020-10-27 | 国家烟草质量监督检验中心 | 烟碱成瘾、戒断和成瘾重建阶段海马组织中基因及对应蛋白表达变化的成组高通量测定方法 |
-
2021
- 2021-09-03 CN CN202111029448.2A patent/CN113462772B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006012356A2 (en) * | 2004-06-23 | 2006-02-02 | Washington University | Methods for determining risk of developing regular smoking behavior |
| WO2008086579A1 (en) * | 2007-01-19 | 2008-07-24 | Queensland University Of Technology | Diagnostic methods and agents |
| CN101050212A (zh) * | 2007-05-18 | 2007-10-10 | 中南大学 | 从废次烟草中同时提取高纯天然烟碱和茄尼醇的方法 |
| WO2013036938A1 (en) * | 2011-09-08 | 2013-03-14 | The Ohio State University | Materials and methods related to dopamine dysregulation disorders |
| CN108251520A (zh) * | 2018-01-31 | 2018-07-06 | 杭州同欣基因科技有限公司 | 一种基于高通量测序技术的吸烟成瘾风险预测方法及戒烟指导方法 |
| CN110317868A (zh) * | 2019-08-09 | 2019-10-11 | 新疆医科大学第二附属医院 | 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法 |
| CN110910956A (zh) * | 2019-11-21 | 2020-03-24 | 刘强 | 单核苷酸多态性检测汉族人群吸烟成瘾方法 |
| CN111518896A (zh) * | 2020-06-28 | 2020-08-11 | 云南中烟工业有限责任公司 | 用于检测尼古丁依赖相关的snp位点的引物组、应用、产品及方法 |
| CN111826436A (zh) * | 2020-07-21 | 2020-10-27 | 国家烟草质量监督检验中心 | 烟碱成瘾、戒断和成瘾重建阶段海马组织中基因及对应蛋白表达变化的成组高通量测定方法 |
Non-Patent Citations (3)
| Title |
|---|
| J YANG等: "Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions", 《MOLECULAR PSYCHIATRY》 * |
| 卞文志: ""尼古丁依赖"被列为一种物质依赖疾病", 《开心老年》 * |
| 许珂等: "不同程度尼古丁依赖者的动态功能网络连接研究", 《临床放射学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113462772B (zh) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6020124A (en) | Detection of soluble gene sequences in biological fluids | |
| CN104630368B (zh) | 一种人运动神经元基因拷贝数相对定量检测方法及试剂盒 | |
| CN110283908B (zh) | 一种结直肠癌辅助诊断snp标志物及其应用 | |
| WO2023142619A1 (zh) | 一种扩张型心肌病基因检测标志物及其应用 | |
| CN104830852A (zh) | 一种检测hla-b*15:02等位基因的多重实时荧光pcr方法 | |
| CN111455044A (zh) | 一种用于母羊早期妊娠诊断的外泌体miRNA标志物及其应用 | |
| CN106755293B (zh) | 一种与肺癌辅助诊断相关的lncRNA标志物及其应用 | |
| CN111518896B (zh) | 用于检测尼古丁依赖相关的snp位点的引物组、应用、产品及方法 | |
| CN110564861A (zh) | 人类Y染色体STR基因座和InDel位点的荧光标记复合扩增试剂盒及其应用 | |
| KR101767644B1 (ko) | 차등 발현 유전자를 이용한 돼지의 산자수 예측용 조성물 및 예측방법 | |
| CN113462772B (zh) | 一种用于检测尼古丁依赖性相关的snp位点的引物组以及应用 | |
| CN101671736A (zh) | 一种用于检测细胞嵌合状态或个体识别的基因检测试剂盒 | |
| CN102816836A (zh) | 一种黄牛fbxo32基因单核苷酸多态性及作为分子标记的检测方法 | |
| CN112410441A (zh) | 利用snp标记kz288479.1_95621鉴别蜂群抗囊状幼虫病性状的方法 | |
| CN112430675A (zh) | 利用snp标记kz288474.1_322717鉴别蜂群抗囊状幼虫病性状的方法 | |
| CN106868128B (zh) | 一组辅助诊断乳腺癌的生物标记物及其应用 | |
| US11021756B2 (en) | MiRNA markers for the diagnosis of osteosarcoma | |
| WO2019027005A1 (ja) | 結核菌遺伝系統特異的に結核症発症のリスクを判定する方法 | |
| CN115747217B (zh) | 长链非编码rna pdxdc1-as1及其应用 | |
| KR102546810B1 (ko) | 자궁경부암의 급성 종양 반응 진단용 조성물 | |
| CN113930505B (zh) | 用于肺癌诊断的试剂盒及装置 | |
| CN114480615B (zh) | 一种用于检测hla-b*5101等位基因的引物组及试剂盒 | |
| CN110205322B (zh) | 一种乳腺癌致病基因sec63的突变snp位点及其应用 | |
| CN118360407A (zh) | 一种与肺癌相关的snp标记、试剂盒及其应用 | |
| CN113943814A (zh) | 肝癌早期筛查的引物探针组合物、试剂盒及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |